The MC should really be $1-1.5B right now given the stage of development for all of IMU's IP and cash on hand, a very surprise massive drop on big volume once 10c was easily broken but that's the market for you.
The market way overvalued IMU's MC at $3.5B with only B-Cell IP where HER-Vaxx wasn't close to Ph2 completion and less cash on hand. Now HER-Vaxx had completed Ph2 with very good final clinical trial result readout, PD1-Vaxx has commence Ph2 clinical trial after promising Ph1 clinical trial completion, CF33 has shown excellent early Ph1 clinical trial update, Ph1 clinical trial for OnCARlytic has started and IMU has added Azer-Cel IP for the blood cancer market.
IMU Price at posting:
5.1¢ Sentiment: None Disclosure: Held
